Pulmonx Corporation

NasdaqGS:LUNG Stock Report

Market Cap: US$242.9m

Pulmonx Future Growth

Future criteria checks 1/6

Pulmonx is forecast to grow earnings and revenue by 9.9% and 17.3% per annum respectively. EPS is expected to grow by 11.2% per annum. Return on equity is forecast to be -106.8% in 3 years.

Key information

9.9%

Earnings growth rate

11.2%

EPS growth rate

Medical Equipment earnings growth17.0%
Revenue growth rate17.3%
Future return on equity-106.8%
Analyst coverage

Good

Last updated12 Dec 2024

Recent future growth updates

Recent updates

Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 27%

Oct 22
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 27%

Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Oct 02
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 15
Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Pulmonx: Low Bar For Q2 Earnings

Jul 21

Slammed 26% Pulmonx Corporation (NASDAQ:LUNG) Screens Well Here But There Might Be A Catch

Jun 07
Slammed 26% Pulmonx Corporation (NASDAQ:LUNG) Screens Well Here But There Might Be A Catch

Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion

Apr 04
Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion

Pulmonx: Revisiting Thesis Following Management Change

Mar 26

Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?

Feb 23
Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?

Market Participants Recognise Pulmonx Corporation's (NASDAQ:LUNG) Revenues

Aug 01
Market Participants Recognise Pulmonx Corporation's (NASDAQ:LUNG) Revenues

Analysts Just Shaved Their Pulmonx Corporation (NASDAQ:LUNG) Forecasts Dramatically

Nov 08
Analysts Just Shaved Their Pulmonx Corporation (NASDAQ:LUNG) Forecasts Dramatically

Pulmonx GAAP EPS of -$0.40 in-line, revenue of $14M beats by $0.23M

Aug 02

Pulmonx: Interesting Technology But Struggling With Adoption

Jul 02

These Analysts Just Made A Meaningful Downgrade To Their Pulmonx Corporation (NASDAQ:LUNG) EPS Forecasts

Feb 28
These Analysts Just Made A Meaningful Downgrade To Their Pulmonx Corporation (NASDAQ:LUNG) EPS Forecasts

Earnings and Revenue Growth Forecasts

NasdaqGS:LUNG - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026117-54N/AN/A5
12/31/202598-64-26N/A6
12/31/202482-61-19N/A6
9/30/202479-57-35-33N/A
6/30/202477-58-36-35N/A
3/31/202473-59-38-37N/A
12/31/202369-61-38-38N/A
9/30/202365-61-40-39N/A
6/30/202361-61-42-41N/A
3/31/202357-59-44-43N/A
12/31/202254-59-46-45N/A
9/30/202252-58-48-46N/A
6/30/202252-54-47-44N/A
3/31/202250-52-51-47N/A
12/31/202148-49-45-41N/A
9/30/202145-45-41-38N/A
6/30/202142-39-37-35N/A
3/31/202133-38-32-30N/A
12/31/202033-32-32-31N/A
9/30/202033-28-27-27N/A
6/30/202032-28-26-25N/A
3/31/202035-22-25-24N/A
12/31/201933-21-21-21N/A
12/31/201820-18-19-18N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LUNG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LUNG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LUNG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LUNG's revenue (17.3% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: LUNG's revenue (17.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: LUNG is forecast to be unprofitable in 3 years.


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:41
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pulmonx Corporation is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Travis SteedBofA Global Research
William PlovanicCanaccord Genuity
John YoungCanaccord Genuity